Sugi Predict

Sugi Predict / Compounds / SCHEMBL7445146

SCHEMBL7445146

SCHEMBL7445146

CN1C(=O)N(CC(CS(=O)(=O)c2ccc(-c3ccc(C(F)(F)F)cc3)cc2)N(O)C=O)C(=O)C1(C)C

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MMP2 P08253 18/20 0.77
▸ MMP1 P03956 15/20 0.77
▸ MMP9 P14780 11/20 0.77
▸ MMP3 P08254 1/20 0.51
▸ CHEK1 O14757 1/20 0.51
▸ AURKA O14965 1/20 0.51
▸ NTRK1 P04629 1/20 0.51
▸ MET P08581 1/20 0.51
▸ PIM1 P11309 1/20 0.51
▸ FGFR1 P11362 1/20 0.51
▸ PRKACA P17612 1/20 0.51
▸ GRK5 P34947 1/20 0.51
▸ MAP2K2 P36507 1/20 0.51
▸ FLT3 P36888 1/20 0.51
▸ MAPK8 P45983 1/20 0.51
▸ MAPK9 P45984 1/20 0.51
▸ CDK8 P49336 1/20 0.51
▸ GSK3B P49841 1/20 0.51
▸ CDK7 P50613 1/20 0.51
▸ CDK9 P50750 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7673801 0.92 MMP2 (0.84) MMP2MMP1MMP9
SCHEMBL7507327 0.88 MMP2 (0.90) MMP2MMP1MMP9MMP3
SCHEMBL7568536 0.88 MMP2 (0.90) MMP2MMP1MMP9MMP3
SCHEMBL8000523 0.87 MMP2 (1.00) MMP2MMP1MMP9MMP3
SCHEMBL7504602 0.87 MMP2 (1.00) MMP2MMP1MMP9MMP3
SCHEMBL7506227 0.85 MMP2 (0.85) MMP2MMP1MMP9MMP3
SCHEMBL7672518 0.84 MMP2 (0.73) MMP2MMP1MMP9MMP3CHEK1
SCHEMBL7676418 0.83 MMP2 (1.00) MMP2MMP1MMP9
SCHEMBL7576504 0.82 MMP2 (0.79) MMP2MMP1MMP9MMP3
SCHEMBL7505455 0.82 MMP2 (0.79) MMP2MMP1MMP9MMP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1001930-B1 N-HYDROXYFORMAMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES ABBOTT LAB (US) 2002-12-04 — — EP claimed
US-20020007060-A1 Reverse hydroxamate inhibitors of matrix metalloproteinases DAVIDSEN STEVEN K (US) 2002-01-17 — — US claimed
EP-1001930-A2 N-HYDROXYFORMAMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES Abbott Laboratories (US) 2000-05-24 — — EP claimed
WO-1999006361-A2 N-HYDROXYFORMAMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES ABBOTT LABORATORIES (US) 1999-02-11 — — WO claimed
EP-1001930-B1 N-HYDROXYFORMAMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES ABBOTT LAB (US) 2002-12-04 — — EP disclosed
US-20020007060-A1 Reverse hydroxamate inhibitors of matrix metalloproteinases DAVIDSEN STEVEN K (US) 2002-01-17 — — US disclosed
US-6294573-B1 FOR THERAPY RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, OSTEOPENIAS SUCH AS OSTEOPOROSIS, PERIODONTITIS, GINGIVITIS, CORNEAL, EPIDERMAL OR GASTRIC ULCERATION, AND TUMOR GROWTH AND METASTASIS OR INVASION ABBOTT LABORATORIES 2001-09-25 — — US disclosed
US-6235786-B1 RHEUMATIC DISORDERS; BONE DISORDERS; ORAL DISEASES; ANTIULCER AGENTS; ANTITUMOR AGENTS ABBOTT LABORATORIES 2001-05-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020007060-A1 Reverse hydroxamate inhibitors of matrix metalloproteinases MMP1, MMP9, MMP3 MMP2 4/4885MMP1 1/4885MMP9 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.